TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28222805

Group type: EXPERIMENTAL
Intervention: Automatic feedback of step count using an activity tracker wristband
Number of subjects: 120

Group type: COMPARATOR
Intervention: No automatic feedback
Number of subjects: 120
Study: 25618800

Group type: EXPERIMENTAL
Intervention: Curcuminoid-piperine combination (1 g curcuminoids + 10 mg piperine daily)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Curcuminoid-piperine combination
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 24335016

Group type: EXPERIMENTAL
Intervention: SAL plus RFAL
Number of subjects: 12

Group type: COMPARATOR
Intervention: SAL alone
Number of subjects: 12
Study: 20513160

Group type: EXPERIMENTAL
Intervention: LCD 15% solution (Psorent)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcipotriene 0.005% cream (Dovonex)
Number of subjects: 60
Study: 18226128

Group type: EXPERIMENTAL
Intervention: Extra-amniotic saline solution infusion (EASI) plus dexamethasone 20 mg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Extra-amniotic saline solution infusion (EASI) alone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Dexamethasone plus EASI
Number of subjects: 84

Group type: COMPARATOR
Intervention: EASI alone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 16967629

Group type: EXPERIMENTAL
Intervention: E2/norgestimate (NGM) 1 mg/90 microg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Unopposed E2 1 mg
Number of subjects: 67
Study: 12837670

Group type: EXPERIMENTAL
Intervention: Risperidone 1 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone 2 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10989586

Group type: EXPERIMENTAL
Intervention: Coltosol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Algenol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fermit
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fermit-N
Number of subjects: 100
Study: 9011450

Group type: EXPERIMENTAL
Intervention: Orlistat (200 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1334255

Group type: EXPERIMENTAL
Intervention: Live oral tetravalent human‐rhesus rotavirus reassortant vaccine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 6519213

Group type: EXPERIMENTAL
Intervention: Erythrapheresis
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo apheresis
Number of subjects: 10
Study: 31131360

Group type: COMPARATOR
Intervention: Open surgery (OP)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Operation time >240 minutes
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Wound complication
Number of subjects: 1057
Study: 29321218

Group type: EXPERIMENTAL
Intervention: Intravenous saline administration
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dietary salt modification
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Angiotensin-II stimulation testing
Number of subjects: 27
Study: 26707353

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 30
Study: 25298578

Group type: EXPERIMENTAL
Intervention: Lafutidine 10 mg once daily for 8 weeks
Number of subjects: 122

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg once daily for 8 weeks
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Lafutidine and Pantoprazole
Number of subjects: 122
Study: 22789793

Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 20302004

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Budesonide 256 microg
Number of subjects: 100
Study: 17958990

Group type: EXPERIMENTAL
Intervention: Acute Bronchitis Severity Score (ABSS)
Number of subjects: 649
Study: 15127186

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4% modified fluid gelatine (GEL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study: 11899903

Group type: EXPERIMENTAL
Intervention: SRL172 with chemotherapy (n=14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Chemotherapy alone (n=14)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both treatment regimens (SRL172 + chemotherapy and chemotherapy alone)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SRL172 with chemotherapy
Number of subjects: 28
Study: 9437338

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Number of subjects: 148

Group type: COMPARATOR
Intervention: Carotid sinus massage (CSM)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Carotid sinus massage (CSM) after Valsalva maneuver
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver after CSM
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Combined Valsalva maneuver and CSM
Number of subjects: 148
Study: 8073455

Group type: EXPERIMENTAL
Intervention: Ancrod
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 2678635

Group type: EXPERIMENTAL
Intervention: Verapamil (VP) therapy prior to administration of CsA
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Verapamil (VP) therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 40
Study: 31479196

Group type: EXPERIMENTAL
Intervention: Myjet-assisted transdermal injection of tranexamic acid (TA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Myjet-assisted transdermal injection of vitamin C (VC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison between TA and VC
Number of subjects: 17
Study: 28918682

Group type: EXPERIMENTAL
Intervention: Classroom training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Classroom training coupled with smartphone app training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Computer training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (traditional face‐to‐face training)
Number of subjects: 50
Study: 28092488

Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 26301771

Group type: EXPERIMENTAL
Intervention: brexpiprazole 3 mg
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: brexpiprazole 1 mg
Number of subjects: 627

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 627
Study: 23735680

Group type: EXPERIMENTAL
Intervention: DEN1Δ30 at 10PFU and 1000PFU doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DEN2/4Δ30 at 10PFU and 1000PFU doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DEN3Δ30/31 at 10PFU and 1000PFU doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DEN1Δ30 at 1000PFU and 10PFU doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DEN2/4Δ30 and DEN3Δ30/31
Number of subjects: 0
Study: 21183518

Group type: EXPERIMENTAL
Intervention: Intracameral lidocaine 1% (0.5 cc)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 506
Study: 19877967

Group type: EXPERIMENTAL
Intervention: Benznidazole (5 mg/kg per day for 30 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study: 16828480

Group type: EXPERIMENTAL
Intervention: Inherited thrombophilia
Number of subjects: 41

Group type: COMPARATOR
Intervention: Women without inherited thrombophilia
Number of subjects: 41
Study: 12956652

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine spray applied twice daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine spray applied once daily plus placebo spray once daily
Number of subjects: 13
Study: 11076106

Group type: EXPERIMENTAL
Intervention: i.v. calcitriol plus calcium carbonate (CaCO3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO3) alone (control)
Number of subjects: 0
Study: 8717610

Group type: EXPERIMENTAL
Intervention: Dietary selenium at 356 micrograms/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dietary selenium at 13 micrograms/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low-selenium group (13 micrograms/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Typical U.S. diet with selenium supplementation
Number of subjects: 11
Study: 1559584

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg (150 mg if B.W. < 40 kg) as a single evening dose for four weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 37
Study: 4042527

Group type: EXPERIMENTAL
Intervention: Bevantolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevantolol with terbutaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30932313

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus (PR-T)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Immediate-release tacrolimus (IR-T)
Number of subjects: 74
Study: 29280806

Group type: EXPERIMENTAL
Intervention: Prenatal connected care model with RNs
Number of subjects: 41

Group type: COMPARATOR
Intervention: Traditional care model (implied control)
Number of subjects: 41
Study: 27769295

Group type: EXPERIMENTAL
Intervention: LMP-based gestational age assessment
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: LMP-based classification of preterm birth
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: LMP-based classification of post-term birth
Number of subjects: 353
Study: 25151658

Group type: EXPERIMENTAL
Intervention: Mometasone nasal spray for six months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Saline nasal spray for six months
Number of subjects: 62
Study: 22370297

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 0
Study: 20034816

Group type: EXPERIMENTAL
Intervention: Patients with abnormal D-dimer who did not resume anticoagulation
Number of subjects: 490

Group type: COMPARATOR
Intervention: Patients with normal D-dimer
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Patients with RVO
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Patients without RVO
Number of subjects: 490
Study: 19851798

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) isomers (3.9 g per day, 50:50 t9c11:c10t12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (high-oleic-acid sunflower oil, 3.9 g per day)
Number of subjects: 25
Study: 16106138

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study: 12384357

Group type: EXPERIMENTAL
Intervention: Ertapenem (INVANZ) at doses up to 3 g
Number of subjects: 0
Study: 10103305

Group type: EXPERIMENTAL
Intervention: GM‐CSF (10 microg/kg/d) by subcutaneous injection for 5 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no GM‐CSF treatment)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 75
Study: 7577779

Group type: EXPERIMENTAL
Intervention: Fentanyl added to mepivacaine (75 micrograms with 30 mL mepivacaine 1.5% with epinephrine 5 micrograms/mL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fentanyl added to mepivacaine
Number of subjects: 20
Study: 2260333

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Naproxen and Sulindac
Number of subjects: 28
Study: 7219899

Group type: EXPERIMENTAL
Intervention: High intensity exercise programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low intensity exercise programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (diet and physical activity without specified intensity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recurrence of myocardial infarction
Number of subjects: 0
Study: 30378087

Group type: EXPERIMENTAL
Intervention: Glycopyrronium tosylate (GT) 3.75% applied once daily for 4 weeks
Number of subjects: 463

Group type: COMPARATOR
Intervention: Vehicle applied once daily for 4 weeks
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Glycopyrronium tosylate (GT)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 463
Study: 28641840

Group type: EXPERIMENTAL
Intervention: 6-month DAPT
Number of subjects: 2021

Group type: COMPARATOR
Intervention: 24-month DAPT
Number of subjects: 2021
Study: 25642584

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relational MI without directive elements (spirit‐only MI)
Number of subjects: 0
Study: 23301674

Group type: EXPERIMENTAL
Intervention: Comprehensive eye assessment including visual acuity, orthoptic assessment, cycloplegic autorefraction, ocular biometric variables, and ophthalmic photographs.
Number of subjects: 1344
Study: 21645997

Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy (CET)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Enriched Supportive Therapy (Control)
Number of subjects: 50
Study: 18423807

Group type: EXPERIMENTAL
Intervention: FX‐E membrane (super-flux)
Number of subjects: 30

Group type: COMPARATOR
Intervention: FX‐60 membrane (high-flux)
Number of subjects: 30
Study: 16503669

Group type: EXPERIMENTAL
Intervention: ECC2 at 100% intensity (n = 12)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ECC2 at 90% intensity (n = 13)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ECC2 at 80% intensity (n = 14)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 51
Study: 12766639

Group type: EXPERIMENTAL
Intervention: Auricular acupressure at the relaxation point
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 36
Study: 10679908

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) alpha and beta (>10 U/mL), long-term exposure (144 hr)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Head and neck squamous cell carcinomas (HNSCC)
Number of subjects: 50
Study: 9358076

Group type: EXPERIMENTAL
Intervention: EPO (600 U/kg, iv, 6 times over 3 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 10
Study: 1606113

Group type: EXPERIMENTAL
Intervention: Monitoring at home
Number of subjects: 99

Group type: COMPARATOR
Intervention: Monitoring in hospital
Number of subjects: 99
Study: 2863380

Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroleptic group (maintenance antipsychotic medication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (drug-free)
Number of subjects: 0
Study: 29581985

Group type: EXPERIMENTAL
Intervention: 3D printing group (n = 50)
Number of subjects: 100
Study: 27259552

Group type: EXPERIMENTAL
Intervention: Once daily antibiotic prophylaxis for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 0
Study: 24261328

Group type: EXPERIMENTAL
Intervention: Citrate-enriched bicarbonate based dialysate (CD) with 30% reduced heparin dose
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acetate-enriched bicarbonate based dialysate with standard heparin dose of ∼ 100 IU/kg (Treatment A)
Number of subjects: 30
Study: 22889151

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) with chemotherapy for 6 months, followed by 3 months follow-up
Number of subjects: 39

Group type: COMPARATOR
Intervention: Chemotherapy without UDCA for 9 months
Number of subjects: 39
Study: 20549040

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 4 mg triamcinolone acetonide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (14 eyes without diabetic macular edema)
Number of subjects: 14
Study: 18826853

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard phosphate-binder therapy (Stx)
Number of subjects: 32
Study: 15796145

Group type: EXPERIMENTAL
Intervention: Protenplus (oral protein-energy supplement)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 65
Study: 12783045

Group type: EXPERIMENTAL
Intervention: Maximal exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 8
Study: 10542989

Group type: EXPERIMENTAL
Intervention: Immunotherapy with heat killed Mycobacterium vaccae
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 40
Study: 8904433

Group type: EXPERIMENTAL
Intervention: famciclovir
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 1906987

Group type: EXPERIMENTAL
Intervention: TPN for 7 to 15 days before surgery and 3 days afterward
Number of subjects: 395

Group type: COMPARATOR
Intervention: No perioperative TPN (control group)
Number of subjects: 395
Study: 6358477

Group type: EXPERIMENTAL
Intervention: seminar and relaxation training
Number of subjects: 71

Group type: COMPARATOR
Intervention: seminar and a placebo condition
Number of subjects: 71

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 71
Study: 28009600

Group type: EXPERIMENTAL
Intervention: High dollar payout category physicians with one malpractice claim payout
Number of subjects: 0

Group type: COMPARATOR
Intervention: All physicians with a single payout
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total dollar payouts per physician
Number of subjects: 0
Study: 30723744

Group type: EXPERIMENTAL
Intervention: Sling surgery alone (S group, n=36)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Concomitant sling and transvaginal mesh surgery (M group, n=40)
Number of subjects: 76
Study: 28687232

Group type: EXPERIMENTAL
Intervention: Mepolizumab (750 mg IV every 4 weeks for 6 doses)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 105
Study: 27468589

Group type: EXPERIMENTAL
Intervention: Memory screw
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hyrax screw
Number of subjects: 32
Study: 24462856

Group type: EXPERIMENTAL
Intervention: Multimedia module (MM)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 21602539

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 143

Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Self-care
Number of subjects: 143
Study: 19244174

Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg injection every 4 weeks for 2 years)
Number of subjects: 2706

Group type: COMPARATOR
Intervention: Tamoxifen (20 or 40 mg daily for 2 years)
Number of subjects: 2706
Study: 17313322

Group type: EXPERIMENTAL
Intervention: O(2) supplementation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 38
Study: 16320180

Group type: EXPERIMENTAL
Intervention: Maitland's manual mobilization, treated two times a week for three weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group, received no treatment
Number of subjects: 36
Study: 12215276

Group type: EXPERIMENTAL
Intervention: Dextran uterine artery embolization
Number of subjects: 38
Study: 9676352

Group type: EXPERIMENTAL
Intervention: Sustained release theophylline (500 mg) with standard breakfast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sustained release theophylline (500 mg) with cholecystokinin (0.3 microgram/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sustained release theophylline (500 mg) under fasting conditions
Number of subjects: 12
Study: 8045953

Group type: EXPERIMENTAL
Intervention: Combined CRH (100 micrograms ovine) and lysine vasopressin (1 IU over 15 min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined CRH and lysine vasopressin
Number of subjects: 10
Study: 3054451

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX, 1,000 mg/m2)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Cranial irradiation/sequential chemotherapy (RTSC)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Historical institutional control regimens
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Both groups (HDMTX and RTSC)
Number of subjects: 330
Study: 29856526

Group type: EXPERIMENTAL
Intervention: Porcine small intestine submucosal graft (SIS)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no graft)
Number of subjects: 47
Study: 27928874

Group type: EXPERIMENTAL
Intervention: Payment for performance (P4P)
Number of subjects: 150
Study: 26026801

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention from a multidisciplinary team
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42
Study: 23894039

Group type: EXPERIMENTAL
Intervention: 1 year trastuzumab treatment
Number of subjects: 425

Group type: COMPARATOR
Intervention: Observation arm (no trastuzumab)
Number of subjects: 425
Study: 21679432

Group type: EXPERIMENTAL
Intervention: Parent-centred, multi-component intervention (balanced information, group discussion, coaching exercise) + MMR information leaflet
Number of subjects: 142

Group type: COMPARATOR
Intervention: Leaflet only (Control)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Both arms (Intervention and Control)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 142
Study: 19080095

Group type: EXPERIMENTAL
Intervention: AHH group (acute hypervolemic hemodilution)
Number of subjects: 36

Group type: COMPARATOR
Intervention: CNT group (control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AHH group
Number of subjects: 36